Clinical Research Directory

Inclusion Criteria: * Patients diagnosed with EoE * Patients less than 21 years of age at enrollment * Patients who within the past 12 months have demonstrated histologic remission (\<15 eos/hpf as assessed by upper esophagogastroduodenoscopy (EGD) with biopsy ) to the standard induction dose of topical steroids and have remained on this treatment: * Topical steroid treatment includes only those with previously published results: Swallowed topical fluticasone (i.e. Flovent®), and Swallowed viscous budesonide (i.e. Pulmicort Respules®) mixed with Honey or Splenda® * Patients who are interested in lowering their dose of topical steroids. Exclusion Criteria: * Patients with EoE who have not demonstrated histologic remission (\<15 eos/hpf) to topical steroids. * Patients who are unable or unwilling to take topical steroids. * Patients who have changed the vehicle or carrier (e.g. Splenda®or honey ) used to mix with the actual steroid drug, after demonstrating histologic remission.